Careers Media center Contacts


Active substance: tranexamic acid

ATC: B02A A02

How supplied: Solution for injection

Dosage form
Solution for injection 5 ml №5.

Active ingredient
1 ml of solution contains 100 mg of tranexamic acid on a 100% substance basis.

Bleeding or risk of bleeding risk with increasing fibrinolysis both generalized (bleeding during surgery and in the postoperative period, postpartum haemorrhage, manual separation of placenta, placental chorionic, bleeding during pregnancy, malignancy, pancreatic and prostate cancer, haemophilia, haemorrhagic complications in fibrinolytic therapy, thrombocytopenic purpura, leukaemia, liver diseases, previous therapy with streptokinase) and local (uterine, nasal, pulmonary, gastrointestinal bleeding, haematuria, bleeding after prostatectomy, cervical conisation due to carcinoma, tooth extraction in patients with haemorrhagic diathesis). Surgeries on the bladder. Surgical manipulations in systemic inflammatory response (sepsis, peritonitis, necrotizing pancreatitis, severe and moderate gestational toxicosis, shock of different aethiology and other critical states).


The following information is intended for medical and pharmaceutical professionals only and can be used exclusively in professional activities.


(submitting the answer, you bear full responsibility for the accuracy of the information provided)

The presented package image matches the product design registered with the Ukrainian regulatory authorities.

If you have noticed any differences, please call us at +380 44 490 75 22


If you have information about any adverse effects or other drug-related problems, please fill in the form